Globus Medical

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Globus Medical achieves record revenue, plans NuVasive merger

Globus Medical (GMED) delivered strong financial performance in 2022, with record revenue and notable growth across key segments.
The planned merger with NuVasive and focus on product innovation position the company for future success and market leadership.
Challenges such as retaining talent and addressing international market dynamics require strategic solutions for sustained growth.
Opportunities lie in diversifying revenue streams, expanding product offerings, and leveraging international markets for continued success.

Globus Medical (GMED) reports record Q1 sales, eyes growth opportunities

Globus Medical (GMED) delivered a strong Q1 performance with record sales and profit growth, driven by strategic initiatives and market demand. While facing challenges like merger delays and potential competition, the company's focus on innovation, technology leadership, and market recognition positions it well for sustained growth and success.

Globus Medical posts record Q2 sales, eyes growth through innovation

Globus Medical delivered a strong Q2 performance with record sales and profitability, driven by innovation and market expansion.
While facing integration challenges post-merger, the company's focus on growth segments and product innovation positions it well for future success.
Opportunities lie in expanding market presence, driving innovation, and capitalizing on technological advancements to sustain growth momentum.

Globus Medical reports record Q3 sales, eyes growth opportunities

Globus Medical's Q3 performance reflects robust sales growth, steady EPS, and progress towards revenue targets, underpinned by innovative product launches and strategic integration efforts.
While facing challenges in hiring and cost synergies, the company's focus on talent acquisition, cost management, and segment-specific strategies positions them well for future growth.
Opportunities lie in new product launches, technological advancements, and streamlined operations through sales force integration, indicating a promising trajectory for Globus Medical's continued success.

Globus Medical (GMED) reports record revenue in 2023, eyes growth amid challenges

Globus Medical (GMED) delivered strong financial results in 2023, driven by the NuVasive merger, with a focus on integration and innovation. While facing challenges from dissynergies and market competition, GMED is poised to capitalize on growth opportunities through strategic initiatives and product launches.

Globus Medical excels in Q1 2024, eyes Enabling Technologies growth

Globus Medical's Q1 2024 showcased exceptional sales growth, margin improvement, and strategic initiatives. Despite challenges in integration and product rollout timing, the company is poised for long-term success. Opportunities in Enabling Technologies and cost leverage position Globus for continued growth.

Globus Medical excels in Q3, eyes margin improvement strategies

Globus Medical's Q3 performance reflects strong financial results, innovation, and market expansion. While challenges in margin improvement persist, the company's strategic focus on cost optimization and product development sets the stage for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GeneDx Holdings Corp

Biotech stock GeneDx broke out after the FDA issued its first AI rules for medical devices. Globus Medical and GeneDx are in buy zones.

Outlook For These Biotechs Brightens As FDA Ushers In New Rules For Sector

Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues

AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis.

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Continues Its Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors.

The Law Offices of Frank R. Cruz Continues Its Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors

This leading medical device maker is showing constructive action in a flat base and setting up for its next move. The post Globus Medical Stock Revs Up For Next Move After 70% Run appeared first on Investor's Business Daily.

Globus Medical Stock Revs Up For Next Move After 70% Run

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term

Boston Scientific

Doximity

LeMaitre Vascular

Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport.

4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow

Globus Medical's synergistic merger with NuVasive and a strong liquidity position bring optimism to investors.

Reasons to Add GMED Stock to Your Portfolio Right Now

Encompass Health

Ensign Group

MEDNAX

Veracyte

The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty.

Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks?

CarGurus

Progyny

Texas Roadhouse

Investors might be well served by expanding beyond the S&P 500.

Four hidden gems in the stock market from a five-star fund manager

Glaukos

Inogen

Intuitive Surgical

Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.

5 Medical Device Stocks That Survived the 2024 Market Volatility

Globus Medical (GMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Globus Medical (GMED) a New Buy Stock

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?

Globus Medical (GMED) Up 2.1% Since Last Earnings Report: Can It Continue?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Globus Medical (GMED) is a Strong Value Stock

Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook Globus Medical (GMED)

Penumbra

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

GMED vs. PEN: Which Stock Should Value Investors Buy Now?

Globus Medical commercially launches ExcelsiusHub navigation system to elevate the standard for freehand navigation.

GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub

AUDUBON, Pa., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ExcelsiusHub™ navigation system. ExcelsiusHub™ joins the expansive ecosystem of Excelsius™ technologies and is designed to elevate the standard for freehand navigation.

Globus Medical Launches ExcelsiusHub™ Navigation System

Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Globus Medical, Inc. (GMED) Hit a 52 Week High, Can the Run Continue?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Globus Medical (GMED) is a Top-Ranked Momentum Stock: Should You Buy?

Why Globus Medical (GMED) is a Top Value Stock for the Long-Term

Globus Medical (GMED) possesses solid growth attributes, which could help it handily outperform the market.

Is Globus Medical (GMED) a Solid Growth Stock? 3 Reasons to Think "Yes"

Expanding Global Market, NuVasive Benefits to Aid GMED Stock

Sonova Holding AG

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two companies is the best option for those looking for undervalued stocks?

News for Globus Medical Stock (GMED)